---

Examines the global issue of biomedical research increasingly failing to deliver patient benefits and health system improvement. The book highlights the problem and its consequences, and analyses the underlying causative factors and provides powerful prescriptions for change to close the ´innovation gap´.

---

Medical innovation as it stands today is fundamentally unsustainable. There is a widening gap between what biomedical research promises and the impact that it is currently achieving, in terms of patient benefit and health system improvement.This book highlights the global problem of the ineffective translation of bioscience innovation into health system improvements and its consequences, analyses the underlying causative factors and provides powerful prescriptions for change to close the gap. It contrasts the progress in biomedicine with other areas of scientific and technological endeavour, such as information technology, in which there are faster and more reliable returns for society.The author´s career has spanned pharmaceuticals, diagnostics and health informatics and he draws lessons from a host of case examples in which bottlenecks have prevented progress, such as in dementia and antibiotic-resistant infections, and from many in which these barriers have been overcome, such as HIV therapy and targeted cancer treatment. The new era of precision medicine holds the greatest promise of closing this ´innovation gap´. Along with techniques such as open innovation and adaptivedevelopment, powerful new genomics and digital health tools are poised to transform the productivity of life sciences.Bioscience-Lost in Translation? lays out a fresh and provocative strategy for advancing the innovation process, shaping the right policy environment and building an ecosystem to deliver the 21st century cures that are urgently needed.

---

Advance Praise: It is not easy to keep up with the rapid pace of biomedical innovation nor changes in society and markets. This book captures exactly where we are right now: an unprecedented wave of innovation that arrives in health systems that are not prepared. And neither is the business model of the pharmaceutical industry. Richard Bergström, Director, European Federation of Pharmaceutical Industry and Associations, Belgium

---

Professor Richard Barker has been Director of CASMI since its creation and was instrumental in its inception and launch. He is a strategic advisor, speaker and author on healthcare and life sciences. Richard has spent most of his career in healthcare, as a leader of organisations, as a board member and as a consultant. His leadership roles have spanned therapeutics, diagnostics and informatics both in the United States and in Europe. He was recently voted as one ofthe top 50 most influential people in UK healthcare and he sits on several healthcare and life sciences advisory boards on both sides of the Atlantic. His passions include securing a sustainable future for healthcare and redesigning how new medical technology is brought into practice. He now lives inLondon but is a frequent visitor to the US, where he spent 11 years working in Boston, New Haven, New York and San Francisco.

---